

CLAIMS

What is claimed is:

- 5 1. A peptide comprising an amino acid sequence of the formula:

$a^1a^2a^3Ca^5a^6a^7a^8a^9a^{10}a^{11}LQSCa^{16}a^{17}a^{18}$ (SEQ ID NO: 276)

wherein:

- 10 a^1 is L, P, W, F, S, Y, N, R, or H;
 a^2 is L, W, F, S, Y, D, or R;
 a^3 is L, I, W, Y, D, or E;
 a^5 is A, L, G, D, E, or K;
 a^6 is A, L, F, S, N, E, K, or H;
 a^7 is L, P, Y, or N;
15 a^8 is A, P, M, F, G, Q, or D;
 a^9 is P, M, T, G, or S;
 a^{10} is A, V, F, H, G, or S;
 a^{11} is V, L, I, F, T, N, or K;
 a^{16} is L, I, W, M, or F;
20 a^{17} is A, G, S, W, or N;
 a^{18} is F, W, or Y; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

- 25 2. The peptide according to Claim 1 wherein:

- a^1 is W;
 a^2 is D;
 a^6 is F;
 a^{10} is A;
30 a^{11} is K;
 a^{16} is F.

3. The peptide according to Claim 1 comprising the amino acid sequence of WDMCHF SHA AKLQSCFPH (SEQ ID NO:273).

5

4. A composition of matter comprising at least one peptide according to Claim 1 and at least one vehicle, wherein said composition of matter is capable of inhibiting NGF activity.

10

5. The composition of matter according to Claim 4 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.


15

6. The peptide according to Claim 1 which is cyclic.

7. A dimer or multimer of the peptide according to Claim 1.

20

8. A composition of matter of the formula:



25 wherein:

F^1 is a Fc domain;

X^1 and X^2 are each independently selected from

$-(L^1)_c-P^1$;

$-(L^1)_c-P^1-(L^2)_d-P^2$;

30

$-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$; and

$-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$;

wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide according to Claim 1;

L^1 , L^2 , L^3 , and L^4 are each independently linkers;
and

5 a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

10 9. The composition of matter according to Claim 8 wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide as shown in SEQ ID NO:273.

15 10. The composition of matter of Claim 8 of the formula: F^1-X^2 .

11. The composition of matter of Claim 8 of the formula: $F^1-(L^1)_c-P^1$.

20

12. The composition of matter of Claim 8 of the formula: $F^1-(L^1)_c-P^1-(L^2)_d-P^2$.

13. The composition of matter of Claim 8 of the
25 formula: $P^1-(L^1)_c-F^1-(L^2)_d-P^2$.

14. The composition of matter of Claim 11 wherein F^1 is an Fc domain or a fragment thereof.

15. The composition of matter of Claim 14 wherein F¹ comprises the amino acid sequence of SEQ ID NO: 60 or a fragment thereof.

5 16. The composition of matter of Claim 15 wherein L¹ is a peptide linker as shown in SEQ ID NO:285.

17. A polynucleotide comprising a polynucleotide sequence encoding the peptide according to Claim 1, 2,
10 3, 6, or 7.

18. An expression vector comprising the polynucleotide of Claim 17.

15 19. A host cell comprising the expression vector of Claim 18.

20. The host cell according to Claim 19 wherein the cell is a prokaryotic cell.

20

21. The host cell according to Claim 20 wherein the cell is an *E. coli* cell.

22. The host cell according to Claim 19 wherein
25 the cell is a eukaryotic cell.

23. A peptide comprising an amino acid sequence of the formula:

$b^1b^2b^3CWb^6b^7b^8b^9Gcb^{12}b^{13}b^{14}$ (SEQ ID NO: 274)

5 wherein:

b^1 is V, L, I, W, T, Y, or E;

b^2 is L, W, M, Q, or H;

b^3 is W, M, G, Q, or E;

b^6 is F or W;

10 b^7 is T or S;

b^8 is A, P, W, S, E, or D;

b^9 is A, G, Q, E, or K;

b^{12} is V, I, P, D, or E;

b^{13} is V, W, or Y; and

15 b^{14} is P, S, or Q; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

24. The peptide according to Claim 23 wherein:

20 b^1 is L or I;

b^2 is Q or H;

b^3 is G or M;

b^6 is F or W;

b^7 is T or S;

25 b^8 is E or D;

b^9 is E or K;

b^{12} is V or E;

b^{13} is V, W, or Y;

b^{14} is P, S, or Q.

30

25. The peptide according to Claim 24 comprising
an amino sequence of IHGCWFTEEGCVWQ (SEQ ID NO: 277).

26. The peptide according to Claim 24 comprising
5 an amino sequence of LQMCWFTEKGCEVP (SEQ ID NO: 278).

27. A composition of matter comprising at least
one peptide according to Claim 23 and at least one
vehicle, wherein said composition of matter is capable
10 of inhibiting NGF activity.

28. The composition of matter according to Claim
27 wherein said vehicle is selected from the group
consisting of a Fc domain, polyethylene glycol, a
15 lipid, a cholesterol group, a carbohydrate, and an
oligosaccharide.

29. The peptide according to Claim 23 which is
cyclic.
20

30. A dimer or multimer of the peptide according
to Claim 23.

31. A composition of matter having the formula:
25 $(X^1)_a-F^1-(X^2)_b,$


wherein:

F^1 is a Fc domain;

X^1 and X^2 are each independently selected from

$-(L^1)_c-P^1;$

30 $-(L^1)_c-P^1-(L^2)_d-P^2;$



wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide according to Claim 23;

5 L^1 , L^2 , L^3 , and L^4 are each independently linkers; and a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

10

32. The composition of matter of Claim 31 wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide as shown as SEQ ID NO: 277.

15

33. The composition of matter of Claim 31 wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide as shown as SEQ ID NO: 278.

20 34. The composition of matter of Claim 31 of the formula: F^1-X^2 .

35. The composition of matter of Claim 32 or Claim 33 of the formula: $F^1-(L^1)_c-P^1$.

25 36. The composition of matter of Claim 31 of the formula: $F^1-(L^1)_c-P^1-(L^2)_d-P^2$.

37. The composition of matter of Claim 31 of the formula: $P^1-(L^1)_c-F^1-(L^2)_d-P^2$.

30

38. The composition of matter of Claim 35, wherein F¹ comprises the amino acid sequence of SEQ ID NO: 60 or a fragment thereof.

5 39. A polynucleotide comprising a polynucleotide sequence encoding the peptide according to Claim 23.

10 40. An expression vector comprising the polynucleotide of Claim 39.

41. A host cell comprising the expression vector of Claim 40.

15 42. The host cell according to Claim 41 wherein the cell is a prokaryotic cell.

43. The host cell according to Claim 42 wherein the cell is an *E. coli* cell.

20 44. The host cell according to Claim 41 wherein the cell is a eukaryotic cell.

25 45. A peptide comprising an amino acid sequence of the formula: c¹c²QCC⁵c⁶Sc⁸c⁹GCC¹²c¹³c¹⁴c¹⁵c¹⁶ wherein:

 c¹ is V, I, T, Y, N, or K;
 c² is L, M, or F;
 c⁵ is S, Q, or E;
 c⁶ is L, F, W, or Y;
30 c⁸ is W, M, T, G, S, or N;
 c⁹ is A, V, G, S, or E;

c¹² is L, P, G, D, or E;

c¹³ is K, I, L, Y, or Q;

c¹⁴ is A, S, P, V, M, or Q;

c¹⁵ is L or absent; and

5 c¹⁶ is E or absent; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

46. The peptide according to Claim 45 wherein:

10 c¹ is K or T;

c² is L or F;

c⁵ is E or Q;

c⁶ is L, F, or Y;

c⁸ is T;

15 c⁹ is S or A; and

c¹² is P or L.

47. A peptide selected from the group consisting of SEQ ID NOS: 208, 209, 224, 233, 234, 241, 246, 279, 20 and 280, or a physiologically acceptable salt thereof, wherein said peptide is capable of inhibiting NGF activity.

48. A composition of matter comprising at least 25 one peptide according to Claim 47 and at least one vehicle, wherein said composition of matter is capable of inhibiting NGF activity.

49. The composition of matter according to Claim 30 48 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a

lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.

50. The peptide according to Claim 47 which is
5 cyclic.

51. A dimer or multimer of the peptide according to Claim 47.

10 52. A composition of matter having the formula:
$$(X^1)_a-F^1-(X^2)_b$$

wherein:

F^1 is a vehicle;

X^1 and X^2 are each independently selected from

15 $-(L^1)_c-P^1$;
 $-(L^1)_c-P^1-(L^2)_d-P^2$;
 $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$; and
 $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$;

wherein one or more of P^1 , P^2 , P^3 , and P^4 each
20 independently comprise a peptide selected from the
group consisting of SEQ ID NOS: 208, 209, 224, 233,
234, 241, 246, 279, and 280;

L^1 , L^2 , L^3 , and L^4 are each independently linkers;
and a, b, c, d, e, and f are each independently 0 or 1,
25 provided that at least one of a and b is 1; or a
physiologically acceptable salt thereof, and wherein
said peptide is capable of inhibiting NGF activity.

53. The composition of matter of Claim 52 of the
30 formula: F^1-X^2 .

54. The composition of matter of Claim 52 of the
formula: $F^1-(L^1)_c-P^1$.

55. The composition of matter of Claim 52 of the
5 formula: $F^1-(L^1)_c-P^1-(L^2)_d-P^2$.

56. The composition of matter of Claim 52 of the
formula: $P^1-(L^1)_c-F^1-(L^2)_d-P^2$.

10 57. The composition of matter of Claim 54,
wherein F^1 is an Fc domain or a fragment thereof.

58. The composition of matter of Claim 57 wherein
 F^1 comprises the amino acid sequence of SEQ ID NO: 60
15 or a fragment thereof.

59. A polynucleotide comprising a polynucleotide
sequence encoding the peptide according to Claim 45.

20 60. An expression vector comprising the
polynucleotide of Claim 59.


61. A host cell comprising the expression vector
of Claim 60.
25

62. The host cell according to Claim 61 wherein
the cell is a prokaryotic cell.

63. The host cell according to Claim 62 wherein
30 the cell is an *E. coli* cell.

64. The host cell according to Claim 61 wherein the cell is a eukaryotic cell.

65. A peptide comprising an amino acid sequence
5 of the formula:



wherein:

- d^1 is a W, Y, Q, or E;
 d^2 is a V, L, F, S, or Q;
10 d^3 is a W, F, G, S, or Q;
 d^4 is a A, Q, D, E, or K;
 d^5 is a V, W, G, or R;
 d^6 is a M, S, Y, Q, N, E, K, or R;
 d^7 is a A, V, L, P, W, Q, or H;
15 d^{10} is a D or E;
 d^{11} is a V or I;
 d^{12} is a V, L, F, or Y;
 d^{13} is a V, L, G, Q, or E;
 d^{14} is a Q, D, or E;
20 d^{15} is a W or C;
 d^{17} is a W, Y, or Q;
 d^{18} is a V, T, Q, N, or K;
 d^{19} is a A, L, or P;
 d^{20} is a P, Q, R, or H;
25 d^{21} is a V, I, W, D;
 d^{22} is a A, I, S, Q, or D;
 d^{23} is a L or absent;
 d^{24} is a E or absent;

or a physiologically acceptable salt thereof, and
30 wherein said peptide is capable of inhibiting NGF activity.

66. The peptide according to Claim 65 wherein:

- d¹ is Q or Y;
d² is L;
5 d³ is W or D;
d⁴ is D, E, or K;
d⁵ is V, W, or G;
d⁶ is Q, K, or R;
d⁷ is W or L;
10 d¹⁰ is E or D;
d¹¹ is V or I;
d¹² is V, L, or F;
d¹³ is V, L, or G;
d¹⁴ is Q, D, or E;
15 d¹⁵ is W or C;
d¹⁷ is W or Y;
d¹⁸ is Q, K, or N;
d¹⁹ is P, V, or L;
d²⁰ is P or S;
20 d²¹ is V;
d²² is Q or D;
d²³ is a L or absent;
d²⁴ is a E or absent.

25 67. A peptide selected from the group consisting of SEQ ID NOS: 203, 228, 240, 247, and 266, inclusive, or a physiologically acceptable salt thereof, wherein said peptide is capable of inhibiting NGF activity.

30 68. A composition of matter comprising at least one peptide according to Claim 65 and at least one

vehicle, wherein said composition of matter is capable of inhibiting NGF activity.


69. The composition of matter according to Claim
5 68 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.

10 70. The peptide according to Claim 65 which is cyclic.

71. A dimer or multimer of the peptide according to Claim 65.

15

72. A composition of matter having the formula:



wherein:

F^1 is a vehicle;

20 X^1 and X^2 are each independently selected from

$-(L^1)_c-P^1$;

$-(L^1)_c-P^1-(L^2)_d-P^2$;

$-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$; and

$-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$;

25 wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide according to Claim 65;

L^1 , L^2 , L^3 , and L^4 are each independently linkers;

and a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1; or a

30 physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

73. The composition of matter of Claim 72 wherein one or more of P^1 , P^2 , P^3 , and P^4 each independently comprise a peptide selected from the group consisting
5 of SEQ ID NOS: 203, 228, 240, 247, and 266.

74. The composition of matter of Claim 73 of the formula: F^1-X^2 .

10 75. The composition of matter of Claim 73 of the formula: $F^1-(L^1)_c-P^1$.

76. The composition of matter of Claim 73 of the formula: $F^1-(L^1)_c-P^1-(L^2)_d-P^2$.

15 77. The composition of matter of Claim 73 of the formula: $P^1-(L^1)_c-F^1-(L^2)_d-P^2$.

78. The composition of matter of Claim 75, wherein F^1 is an Fc domain or a fragment thereof.

20

79. The composition of matter of Claim 78 wherein F^1 comprises the amino acid sequence of SEQ ID NO: 60 or a fragment thereof.

25 80. A polynucleotide comprising a polynucleotide sequence encoding the peptide according to Claim 65.

81. An expression vector comprising the polynucleotide of Claim 80.

30

82. A host cell comprising the expression vector of Claim 81.

83. The host cell according to Claim 82 wherein
5 the cell is a prokaryotic cell.

84. The host cell according to Claim 83 wherein the cell is an *E. coli* cell.

10 85. The host cell according to Claim 82 wherein the cell is a eukaryotic cell.

86. A peptide comprising an amino acid sequence of the formula:

15 f¹f²f³f⁴f⁵f⁶f⁷f⁸f⁹f¹⁰f¹¹Lf¹³EQYFf¹⁸Lf²⁰PPGf²⁴f²⁵f²⁶

wherein:

f¹ is A or absent;
f² is Q or absent;
f³ is L, M, T, Q or N;
20 f⁴ is A, I, P, T, G, or Q;
f⁵ is M, G, E, or D;
f⁶ is W or H;
f⁷ is L, P, or M;
f⁸ is G, L, R, or S;
25 f⁹ is A, Q, D, or E;
f¹⁰ is L, N, or M;
f¹¹ is P, R, or S;
f¹³ is L, F, or Y;
f¹⁸ is A, Q, E, or R;
30 f²⁰ is T, M, or I;
f²⁴ is L, I, V, or Y;

f²⁵ is a L or absent; and
f²⁶ is a E or absent, or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

5

87. The peptide according to Claim 86 wherein:

f¹ is A or absent;
f² is Q or absent;
f³ is M, Q, or N;
10 f⁴ is I, P, T, or G;
f⁵ is M, G, or D;
f⁶ is W or H;
f⁷ is L or P;
f⁸ is G, L, or S;
15 f⁹ is A, Q, or D;
f¹⁰ is L, N, or M;
f¹¹ is P, R, or S;
f¹³ is L or F;
f¹⁸ is A, Q, or E;
20 f²⁰ is T, M, or I;
f²⁴ is L, I, or V;
f²⁵ is a L or absent;
f²⁶ is a E or absent.

25

88. A peptide selected from the group consisting of SEQ ID NOS: 210, 230, 232, 236, 239, and 251, inclusive, or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

30

89. A composition of matter comprising at least one peptide according to Claim 86 and at least one vehicle, and wherein said peptide is capable of inhibiting NGF activity.

5

90. The composition of matter according to Claim 89 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.


10

91. The peptide according to Claim 86 which is cyclic.

15

92. A dimer or multimer of the peptide according to Claim 86.

93. A composition of matter having the formula:



20 wherein:

F^1 is a vehicle;

X^1 and X^2 are each independently selected from

$-(L^1)_c-P^1$;

$-(L^1)_c-P^1-(L^2)_d-P^2$;

25

$-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$; and

$-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$;

wherein one or more of P^1 , P^2 , P^3 , and P^4 each

independently comprise a peptide according to Claim 86;

L^1 , L^2 , L^3 , and L^4 are each independently linkers;

30

and a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1; or a

physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

94. The composition of matter of claim 93 wherein
5 one or more of P^1 , P^2 , P^3 , and P^4 each independently
comprise a peptide selected from the group consisting
of SEQ ID NOS: 210, 230, 232, 236, 239, and 251.

95. The composition of matter of Claim 93 of the
10 formula: F^1-X^2 .

96. The composition of matter of Claim 93 of the
formula: $F^1-(L^1)_c-P^1$.

15 97. The composition of matter of Claim 93 of the
formula: $F^1-(L^1)_c-P^1-(L^2)_d-P^2$.

98. The composition of matter of Claim 93 of the
formula: $P^1-(L^1)_c-F^1-(L^2)_d-P^2$.

20 99. The composition of matter of Claim 96 wherein
 F^1 is an Fc domain or a fragment thereof.

100. The composition of matter of Claim 96
wherein F^1 comprises the amino acid sequence of SEQ ID
25 NO: 60 or a fragment thereof.

101. A polynucleotide comprising a polynucleotide
sequence encoding the peptide according to Claim 86.

30 102. An expression vector comprising the
polynucleotide of Claim 101.

103. A host cell comprising the expression vector of Claim 102.


5 104. The host cell according to Claim 103 wherein the cell is a prokaryotic cell.

105. The host cell according to Claim 104 wherein the cell is an *E. coli* cell.

10

106. The host cell according to Claim 103 wherein the cell is a eukaryotic cell.

107. A peptide comprising an amino acid sequence
15 of the formula:



wherein:

- h¹ is A or absent;
h² is Q or absent;
20 h³ is V, G, P, or absent;
h⁴ is V, T, S, K, or absent;
h⁵ is S, E, Q, or D;
h⁶ is Q, N, K, or M;
h⁹ is S, G, Q, or D;
25 h¹⁰ is W, Y, or F;
h¹¹ is A, L, or M;
h¹³ is Q, N, or Y;
h¹⁶ is K, H, S, or R;
h¹⁸ is A, V, L, or I;
30 h²² is S, T, or G;
h²³ is L or absent;

h²⁴ is E or absent; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

- 5 108. The peptide according to Claim 107 wherein:
 h¹ is A or absent;
 h² is Q or absent;
 h³ is P or absent;
 h⁴ is T or absent;
10 h⁵ is E or D;
 h⁶ is Q or N;
 h⁹ is E or D;
 h¹⁰ is W or Y;
 h¹¹ is L or M;
15 h¹³ is Q or N;
 h¹⁶ is K or R;
 h¹⁸ is V or L;
 h²² is S or T;
 h²³ is L or absent;
20 h²⁴ is E or absent.

109. A peptide selected from the group consisting of SEQ ID NOS: 202, 211, 219, 221, 231, 237, and 272, inclusive, or a physiologically acceptable salt
25 thereof, and wherein said peptide is capable of inhibiting NGF activity.

110. A composition of matter comprising at least one peptide according to Claim 107 and at least one
30 vehicle, and wherein said peptide is capable of inhibiting NGF activity.

111. A composition of matter comprising at least one peptide selected from the group consisting of SEQ ID NOS: 202, 211, 219, 221, 231, 237, and 272, inclusive, and a vehicle, and wherein said composition of matter is capable of inhibiting NGF activity.

112. The composition of matter according to Claim 110 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.


113. The composition of matter according to Claim 111 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.

114. The peptide according to Claim 107 which is cyclic.

115. A dimer or multimer of the peptide according to Claim 107.

25

116. A composition of matter having the formula:



wherein:

F^1 is a vehicle;

30 X^1 and X^2 are each independently selected from

- (L¹)_c-P¹;
- (L¹)_c-P¹-(L²)_d-P²;
- (L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³; and
- (L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³-(L⁴)_f-P⁴;

5 wherein one or more of P¹, P², P³, and P⁴ each independently comprise a peptide according to Claim 107;

L¹, L², L³, and L⁴ are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1,
10 provided that at least one of a and b is 1; or a physiologically acceptable salt thereof, and wherein said peptide is capable of inhibiting NGF activity.

117. The composition of matter of Claim 116
15 wherein one or more of P¹, P², P³, and P⁴ each independently comprise a peptide selected from the group consisting of SEQ ID NOS: 202, 211, 219, 221, 231, 237, and 272.

20 118. The composition of matter of Claim 117 of the formula: F¹-X².

119. The composition of matter of Claim 117 of the formula: F¹-(L¹)_c-P¹.

25

120. The composition of matter of Claim 117 of the formula: F¹-(L¹)_c-P¹-(L²)_d-P².

121. The composition of matter of Claim 117 of the formula: P¹-(L¹)_c-F¹-(L²)_d-P².

30

122. The composition of matter of Claim 119 wherein F¹ is an Fc domain or a fragment thereof.

123. The composition of matter of Claim 122
5 wherein F¹ comprises the amino acid sequence of SEQ ID NO: 60 or a fragment thereof.

124. The composition of matter of Claim 123
10 wherein P¹ is a peptide of SEQ ID NO:219 and L¹ is a peptide of SEQ ID NO:285.

125. The composition of matter of Claim 123
15 wherein P¹ is a peptide of SEQ ID NO:219 and L¹ is a peptide of SEQ ID NO:286.

126. A polynucleotide comprising a polynucleotide sequence encoding the peptide according to Claim 113.

127. An expression vector comprising the
20 polynucleotide of Claim 126.


128. A host cell comprising the expression vector of Claim 127.

25 129. The host cell according to Claim 128 wherein the cell is a prokaryotic cell.

130. The host cell according to Claim 129 wherein the cell is an *E. coli* cell.

131. The host cell according to Claim 128 wherein the cell is a eukaryotic cell.

132. A composition of matter comprising an amino acid sequence of the formula:



wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from
10 $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$,
and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$;

L^1 , L^2 , L^3 , and L^4 are each independently linkers;

a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1; and

15 P^1 , P^2 , P^3 , and P^4 are each independently sequences selected from the group consisting of:

i. SEQ ID NO: 1 to SEQ ID NO: 58, inclusive;

ii. SEQ ID NO: 202 to SEQ ID NO: 280,


inclusive;

20 iii. an analog of (i) or (ii); and

iv. a derivative of (i), (ii) or (iii); or a physiologically acceptable salt thereof, and wherein said composition of matter is capable of inhibiting NGF activity.

25

133. The composition of matter of Claim 132 comprising an amino acid sequence of the formula:



wherein:

30 F^1 is an Fc domain;

L is a linker; and

P is selected from the group consisting of:

- i. SEQ ID NOS: 8, 10, 23, and 24;
- ii. an analog of (i); and
- iii. a derivative of (i) or (ii); or a

5 physiologically acceptable salt thereof, and wherein said composition of matter is capable of inhibiting NGF activity.

134. A method of treating or preventing a disease
10 or disorder associated with NGF activity comprising administering, to a human or animal subject, a therapeutically effective amount of a composition of matter according to Claim 124, 125, 156, 157, 158, 159, 160, 161, 162, or 163.

15

135. The method according to Claim 134 wherein the disease or disorder is selected from the group consisting of neurologic pain, painful diabetic neuropathy, post-herpetic neuralgia, inflammatory pain,
20 migraine, asthma, hyperactive bladder, psoriasis and cancer.

136. The method of Claim 134 wherein the disease or disorder is pain.

25

137. The method of Claim 134 wherein the disease or disorder is selected from the group consisting of acute pain, dental pain, pain from trauma, surgical pain, pain resulting from amputation or abscess,
30 causalgia, demyelinating diseases, trigeminal neuralgia, cancer, chronic alcoholism, stroke, thalamic

pain syndrome, diabetes, acquired immune deficiency syndrome ("AIDS"), toxins and chemotherapy, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general
5 inflammation, arthritis, rheumatic diseases, lupus, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, sunburn, carditis, dermatitis,
10 myositis, neuritis, collagen vascular diseases, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained
15 pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, post-herpetic neuralgia, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin
20 reactions, pruritis, vitiligo, general gastrointestinal disorders, colitis, gastric ulceration, duodenal ulcers, vasomotor or allergic rhinitis, or bronchial disorders.

25 138. A method for inhibiting pain or promoting analgesia comprising administering, to a human or animal subject, a therapeutically effective amount of a composition of matter according to Claim 124, 125, 156, 157, 158, 159, 160, 161, 162, or 163

139. A peptide comprising an amino acid sequence selected from the group consisting of:

i. SEQ ID NOS: 8, 10, 23, or 24;

ii. an analog of (i); and

5 iii. a physiologically acceptable salt of (i) or (ii), wherein said peptide is capable of inhibiting NGF activity.

140. A composition of matter comprising at least
10 one peptide according to Claim 139 and at least one vehicle, wherein said composition of matter is capable of inhibiting NGF activity.


141. The composition of matter according to Claim
15 140 wherein said vehicle is selected from the group consisting of a Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.

20 142. The peptide according to Claim 139 which is cyclic.

143. A dimer or multimer of the peptide according to Claim 139.

25

144. A composition of matter having the formula:



wherein:

F^1 is a vehicle;

30 X^1 and X^2 are each independently selected from

- (L¹)_c-P¹;
- (L¹)_c-P¹-(L²)_d-P²;
- (L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³; and
- (L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³-(L⁴)_f-P⁴;

5 wherein one or more of P¹, P², P³, and P⁴ each
independently comprise a peptide according to Claim
139;

L¹, L², L³, and L⁴ are each independently linkers;
and a, b, c, d, e, and f are each independently 0 or 1,
10 provided that at least one of a and b is 1; or a
physiologically acceptable salt thereof, and wherein
said peptide is capable of inhibiting NGF activity.

145. The composition of matter of Claim 144 of
15 the formula: F¹-X².

146. The composition of matter of Claim 144 of
the formula: F¹-(L¹)_c-P¹.

20 147. The composition of matter of Claim 144 of
the formula: F¹-(L¹)_c-P¹-(L²)_d-P².

148. The composition of matter of Claim 144 of
the formula: P¹-(L¹)_c-F¹-(L²)_d-P².

25 149. The composition of matter of Claim 145,
wherein F¹ is an Fc domain or a fragment thereof.

150. A polynucleotide comprising a polynucleotide
30 sequence encoding the peptide according to Claim 139.

151. An expression vector comprising the polynucleotide of Claim 150.

152. A host cell comprising the expression vector
5 of Claim 151.

153. The host cell according to Claim 152 wherein the cell is a prokaryotic cell.

10 154. The host cell according to Claim 153 wherein the cell is an *E. coli* cell.

155. The host cell according to Claim 152 wherein the cell is a eukaryotic cell.
15

156. The composition of matter of Claim 58 wherein P¹ is a peptide of SEQ ID NO:241 and L¹ is a peptide of SEQ ID NO:285.

20 157. The composition of matter of Claim 58 wherein P¹ is a peptide of SEQ ID NO:241 and L¹ is a peptide of SEQ ID NO:286.

25 158. The composition of matter of Claim 96 wherein P¹ is a peptide of SEQ ID NO:251 and L¹ is a peptide of SEQ ID NO:285.

30 159. The composition of matter of Claim 96 wherein P¹ is a peptide of SEQ ID NO:251 and L¹ is a peptide of SEQ ID NO:286.

160. The composition of matter of Claim 54 wherein P is the peptide shown in SEQ ID NO:224 and L¹ is the peptide linker shown in SEQ ID NO:285.

5 161. The composition of matter of Claim 54 wherein P¹ is a peptide of SEQ ID NO:224 and L¹ is a peptide of SEQ ID NO:286.

10 162. The composition of matter of Claim 96 wherein P¹ is the peptide shown in SEQ ID NO:239 and L¹ is the peptide shown in SEQ ID NO:285.

15 163. The composition of matter of Claim 96 wherein P¹ is a peptide of SEQ ID NO:239 and L¹ is a peptide of SEQ ID NO:286.